Gut microbiota perturbations in response to SARS-CoV-2 and survival outcomes in patients with cancer.

A Alba Santiago Badenas (Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) N Nuria Moragas Garcia (Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain) F Fiorella Ruiz-Pace (Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) M Mireia Obon Santacana (Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain) I Iosune Baraibar (5Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, Vall d'Hebron University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain) M Maria Vieito Villar (Vall d'Hebron Institute of Oncology, Barcelona, Spain) A Ariadna Garcia (Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain) L Laura Boleda Monferrer (Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) M Mafalda Oliveira (Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona) A Andri Papakonstantinou N Nuria Mulet Margalef (Medical Oncology Department, Catalan Institute of Oncology (ICO), L´Hospitalet De Llobregat, Barcelona, Spain) P Paula Gubern Prieto (Medical Oncology Department, Catalan Institute of Oncology (ICO), Barcelona, Spain) E Elisabet Guino (Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain) S Stefania Napoli (Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) J Juan Aguilar-Company (Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain) C Cristina Saura Manich (Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain) E Elena Garralda E Elena Elez (Vall d’Hebron Hospital Campus, Barcelona) V Víctor Moreno P Paolo Nuciforo

Abstract

178 Background: The gut microbiota plays a critical role in immune function, but in diseases such as cancer, dysbiosis may increase vulnerability to external factors like viral infections. In this study, we investigated the impact of gut microbiota in relation to SARS-CoV-2 infection in cancer patients. Methods: Stools collected at recruitment underwent shotgun metagenomic sequencing and inflammatory cytokine profiling using ELISA. Taxonomy data were correlated with infection status, disease severity and mortality. All analyses were adjusted for age, sex, smoking status, tumor type, stage at COVID-19 diagnosis, comorbidities, and vaccination. Results: A total of 195 patients with solid tumors (colon=60, breast=43, miscellaneous=92) were prospectively enrolled. SARS-CoV-2-infected cancer patients (n=98) showed reduced α-diversity (Shannon and Chao1 indexes, p=0.002) and a distinct microbial composition (p=0.004) with Enterococcus spp. enrichment ( E.A avium, E.B faecium, E. faecalis ) compared to non-infected patients (n=97). Hospitalized patients due to severe SARS-CoV-2 infection exhibited depletion of several commensal species including Eubacterium spp. and Lachnospira spp., which were positively correlated with gut immune response assessed by stool cytokines. In an adjusted logistic model of overall survival, SARS-CoV-2 infection was significantly associated to higher all-cause mortality (OR=4.56; 95%CI: 2.16–10.03; p<0.0001). Forty-four taxa (32 depleted and 12 enriched) could differentiate deceased vs alive patients, independently of SARS-CoV-2 infection status. These severity-related microbiota composition correlated with the magnitude of systemic inflammatory response with increased concentration of blood C reactive protein, lactate dehydrogenase, and lymphopenia with depletion of commensals. Conclusions: Depletion of protective gut commensals and enrichment of pathogens may impair immune sensing and response to viral infections ultimately contributing to the hyperinflammatory state and lymphodepletion linked with severe disease and mortality. The lack of cohort-specific taxa suggests that the higher mortality induced by SARS-CoV-2 in cancer patients may be driven by a pre-existing dysbiosis.

Article Details

Volume / Issue Vol. 44, Issue 2_suppl
Published January 10, 2026
Pages 178-178
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

A

Alba Santiago Badenas

Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

N

Nuria Moragas Garcia

Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain

F

Fiorella Ruiz-Pace

Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

M

Mireia Obon Santacana

Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain

I

Iosune Baraibar

5Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Department, Vall d'Hebron University Hospital, University Autonoma of Barcelona (UAB), Barcelona, Spain

M

Maria Vieito Villar

Vall d'Hebron Institute of Oncology, Barcelona, Spain

A

Ariadna Garcia

Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

L

Laura Boleda Monferrer

Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

M

Mafalda Oliveira

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona

A

Andri Papakonstantinou

N

Nuria Mulet Margalef

Medical Oncology Department, Catalan Institute of Oncology (ICO), L´Hospitalet De Llobregat, Barcelona, Spain

P

Paula Gubern Prieto

Medical Oncology Department, Catalan Institute of Oncology (ICO), Barcelona, Spain

E

Elisabet Guino

Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Barcelona, Spain

S

Stefania Napoli

Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

J

Juan Aguilar-Company

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

C

Cristina Saura Manich

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

E

Elena Garralda

E

Elena Elez

Vall d’Hebron Hospital Campus, Barcelona

V

Víctor Moreno

P

Paolo Nuciforo